| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/10/2023 | -4.29% | Morgan Stanley | $38 → $33 | Maintains | Underweight |
| 10/12/2023 | -7.19% | Barclays | $37 → $32 | Maintains | Underweight |
| 08/07/2023 | 7.31% | Barclays | $36 → $37 | Maintains | Underweight |
| 07/20/2023 | 4.41% | Barclays | $40 → $36 | Maintains | Underweight |
| 05/12/2023 | 16.01% | Barclays | $38 → $40 | Maintains | Underweight |
| 05/10/2023 | 53.71% | Canaccord Genuity | $52 → $53 | Maintains | Buy |
| 05/10/2023 | 10.21% | Morgan Stanley | $35 → $38 | Maintains | Underweight |
| 04/05/2023 | 36.31% | UBS | → $47 | Initiates Coverage On | → Neutral |
| 02/10/2023 | 10.21% | Barclays | $37 → $38 | Maintains | Underweight |
| 02/09/2023 | 53.71% | RBC Capital | → $53 | Reiterates | → Outperform |
| 02/09/2023 | 50.81% | Canaccord Genuity | $48 → $52 | Maintains | Buy |
| 11/17/2022 | 39.21% | Canaccord Genuity | → $48 | Initiates Coverage On | → Buy |
| 11/14/2022 | 1.51% | Barclays | $31 → $35 | Maintains | Underweight |
| 11/11/2022 | 1.51% | Morgan Stanley | $36 → $35 | Maintains | Underweight |
| 11/11/2022 | 27.61% | Wells Fargo | $43 → $44 | Maintains | Overweight |
| 11/07/2022 | 24.71% | Wells Fargo | $46 → $43 | Maintains | Overweight |
| 10/26/2022 | 21.81% | Goldman Sachs | $47 → $42 | Downgrades | Buy → Neutral |
| 10/17/2022 | 4.41% | Morgan Stanley | $40 → $36 | Downgrades | Equal-Weight → Underweight |
| 08/08/2022 | -4.29% | Barclays | $29 → $33 | Maintains | Underweight |
| 08/03/2022 | 27.61% | Wells Fargo | $39 → $44 | Maintains | Overweight |
| 05/12/2022 | -15.89% | Barclays | $34 → $29 | Maintains | Underweight |
| 05/11/2022 | 13.11% | Morgan Stanley | $43 → $39 | Maintains | Equal-Weight |
| 05/11/2022 | 13.11% | Wells Fargo | $43 → $39 | Maintains | Overweight |
| 02/10/2022 | 24.71% | Morgan Stanley | $46 → $43 | Maintains | Equal-Weight |
| 02/09/2022 | 36.31% | Wells Fargo | $55 → $47 | Maintains | Overweight |
| 09/28/2021 | 7.31% | Wells Fargo | $39 → $37 | Maintains | Underweight |
| 08/06/2021 | 50.81% | RBC Capital | $50 → $52 | Maintains | Outperform |
| 07/14/2021 | — | Raymond James | Initiates Coverage On | → Market Perform | |
| 05/07/2021 | 24.71% | Morgan Stanley | $36 → $43 | Maintains | Equal-Weight |
| 12/08/2020 | -12.99% | Wells Fargo | → $30 | Initiates Coverage On | → Underweight |
| 11/19/2020 | 24.71% | RBC Capital | $36 → $43 | Maintains | Outperform |
| 11/13/2020 | -4.29% | Morgan Stanley | $31 → $33 | Maintains | Equal-Weight |
| 10/14/2020 | -10.09% | Morgan Stanley | $29 → $31 | Maintains | Equal-Weight |
| 08/05/2020 | -15.89% | Morgan Stanley | $30 → $29 | Maintains | Equal-Weight |
| 08/05/2020 | -12.99% | Deutsche Bank | $38 → $30 | Maintains | Hold |
| 07/13/2020 | -12.99% | Morgan Stanley | $28 → $30 | Maintains | Equal-Weight |
| 05/08/2020 | -18.79% | Morgan Stanley | $27 → $28 | Maintains | Equal-Weight |
| 05/08/2020 | -12.99% | Citigroup | $36 → $30 | Maintains | Neutral |
| 02/28/2020 | 62.41% | Goldman Sachs | → $56 | Reinstates | → Buy |
| 02/12/2020 | 13.11% | Morgan Stanley | $32 → $39 | Maintains | Equal-Weight |
| 02/11/2020 | 24.71% | Citigroup | $38 → $43 | Downgrades | Buy → Neutral |
| 02/10/2020 | 18.91% | CFRA | $33 → $41 | Maintains | Hold |
| 02/10/2020 | — | Consumer Edge Research | Upgrades | Equal-Weight → Overweight | |
| 11/13/2019 | -1.39% | UBS | $35 → $34 | Maintains | Neutral |
| 09/03/2019 | -7.19% | Morgan Stanley | $35 → $32 | Maintains | Equal-Weight |
| 07/08/2019 | 16.01% | SunTrust Robinson Humphrey | $35 → $40 | Upgrades | Hold → Buy |
| 04/16/2019 | 18.91% | Wells Fargo | $39 → $41 | Maintains | Market Perform |
| 02/08/2019 | — | B of A Securities | Upgrades | Underperform → Neutral | |
| 11/15/2018 | 45.01% | Citigroup | $65 → $50 | Maintains | Buy |
| 11/14/2018 | 24.71% | Deutsche Bank | $49 → $43 | Maintains | Hold |
| 11/14/2018 | 33.41% | UBS | $51 → $46 | Maintains | Neutral |
What is the target price for Edgewell Personal Care (EPC)?
The latest price target for Edgewell Personal Care (NYSE: EPC) was reported by Morgan Stanley on November 10, 2023. The analyst firm set a price target for $33.00 expecting EPC to fall to within 12 months (a possible -4.29% downside). 15 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Edgewell Personal Care (EPC)?
The latest analyst rating for Edgewell Personal Care (NYSE: EPC) was provided by Morgan Stanley, and Edgewell Personal Care maintained their underweight rating.
When is the next analyst rating going to be posted or updated for Edgewell Personal Care (EPC)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Edgewell Personal Care, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Edgewell Personal Care was filed on November 10, 2023 so you should expect the next rating to be made available sometime around November 10, 2024.
Is the Analyst Rating Edgewell Personal Care (EPC) correct?
While ratings are subjective and will change, the latest Edgewell Personal Care (EPC) rating was a maintained with a price target of $38.00 to $33.00. The current price Edgewell Personal Care (EPC) is trading at is $34.48, which is out of the analyst's predicted range.